Bavarian Nordic (OTCMKTS:BVNRY) Shares Gap Down – Here’s Why

Bavarian Nordic (OTCMKTS:BVNRY) shares gapped down prior to trading on Tuesday . The stock had previously closed at $11.44, but opened at $10.88. Bavarian Nordic shares last traded at $10.88, with a volume of 556 shares trading hands.

Bavarian Nordic Stock Down 3.0%

The stock has a fifty day moving average of $9.82 and a two-hundred day moving average of $9.77. The stock has a market cap of $2.49 billion, a price-to-earnings ratio of 10.59 and a beta of 1.20.

Bavarian Nordic (OTCMKTS:BVNRY) last released its quarterly earnings data on Friday, August 21st. The company reported $0.46 earnings per share (EPS) for the quarter. Bavarian Nordic had a net margin of 24.36% and a return on equity of 12.06%. The company had revenue of $316.47 million during the quarter.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.